GSK, J&J Join Index Ventures' Asset-Based $199M VC Fund
By Nuala Moran
Wednesday, March 28, 2012
LONDON Spring has arrived on cue for European biotech with the launch of a new €150 million (US$199 million) venture capital fund from Index Ventures with backing and active involvement from two pharma partners, GlaxoSmithKline plc and Johnson & Johnson to specialize in investing in early stage companies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.